NCT01905813 2025-12-19
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Incyte Corporation
Phase 1 Active not recruiting
Clinical Trials
7 trialsNCT04170283 2025-10-21
Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies
BeOne Medicines
Phase 3 Active not recruiting
NCT02457598 2025-06-17
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Gilead Sciences
Phase 1 Terminated
NCT06958679 2025-05-14
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1 Recruiting
NCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
NCT02343120 2022-04-28
Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
BeiGene
Phase 1/2 Completed
NCT03701438 2020-02-20
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Gilead Sciences
Terminated